文献速递神经肿瘤

联合免疫治疗:可控白细胞介素-12基因治疗与免疫检查点阻断在复发胶质母细胞瘤中的开放标签多机构Ⅰ期试验

Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.
PubMed 文献 · Neuro Oncol · 2022-01-01

该开放标签、多机构、剂量递增Ⅰ期试验在21例复发胶质母细胞瘤受试者中评估可控IL-12基因治疗联合纳武利尤单抗的安全性。联合治疗毒性可预测、剂量相关且停药可逆,血清IL-12约在术后第3天达峰,VDX 10 mg联合纳武利尤单抗的中位总生存期为16.9个月,全部受试者为9.8个月。

要点

  • 联合治疗毒性可预测、剂量相关且停药可逆
  • 血清IL-12水平在所有受试者中约术后第3天达峰
  • VDX 10 mg联合纳武利尤单抗的中位总生存期为16.9个月,全部受试者为9.8个月

核心结论

  • 该联合免疫治疗的安全性已确立,并促成一项正在进行的免疫检查点阻断联合可控IL-12基因治疗的Ⅱ期临床试验(NCT04006119)。

研究设计与样本

  • 开放标签、多机构、剂量递增Ⅰ期试验(NCT03636477),在复发胶质母细胞瘤受试者中纳入21例,分3个剂量递增队列。
  • 队列1:新辅助后持续纳武利尤单抗(1 mg/kg)联合VDX(10 mg),n=3。
  • 队列2:新辅助后持续纳武利尤单抗(3 mg/kg)联合VDX(10 mg),n=3。
  • 队列3:新辅助后持续纳武利尤单抗(3 mg/kg)联合VDX(20 mg),n=15。
  • 纳武利尤单抗在复发胶质母细胞瘤切除前7(±3)天给药,随后瘤周注射IL-12基因治疗;VDX在术前3小时及术后14天给药;纳武利尤单抗术后每两周给药。

主要发现

  • 联合治疗的毒性与IL-12基因单药治疗相当,可预测、剂量相关,且在停用VDX和/或纳武利尤单抗后逆转。
  • VDX血浆药代动力学显示剂量-反应关系,脑肿瘤组织VDX穿透有效并产生IL-12。
  • 所有受试者血清IL-12水平约在术后第3天达峰。
  • 治疗后活检显示肿瘤IFNγ增加。
  • VDX 10 mg联合纳武利尤单抗的中位总生存期为16.9个月,全部受试者为9.8个月。

关键数值与推荐

  • 队列1:纳武利尤单抗1 mg/kg联合VDX 10 mg,n=3。
  • 队列2:纳武利尤单抗3 mg/kg联合VDX 10 mg,n=3。
  • 队列3:纳武利尤单抗3 mg/kg联合VDX 20 mg,n=15。
  • 纳武利尤单抗在切除前7(±3)天给药,术后每两周给药。
  • VDX在术前3小时及术后14天给药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Veledimex (VDX)-regulatable interleukin-12 (IL-12) gene therapy in recurrent glioblastoma (rGBM) was reported to show tumor infiltration of CD8+ T cells, encouraging survival, but also up-regulation of immune checkpoint signaling, providing the rationale for a combination trial with immune checkpoint inhibition. METHODS: An open-label, multi-institutional, dose-escalation phase I trial in rGBM subjects (NCT03636477) accrued 21 subjects in 3 dose-escalating cohorts: (1) neoadjuvant then ongoing nivolumab (1mg/kg) and VDX (10 mg) (n = 3); (2) neoadjuvant then ongoing nivolumab (3 mg/kg) and VDX (10 mg) (n = 3); and (3) neoadjuvant then ongoing nivolumab (3 mg/kg) and VDX (20 mg) (n = 15). Nivolumab was administered 7 (±3) days before resection of the rGBM followed by peritumoral injection of IL-12 gene therapy. VDX was administered 3 hours before and then for 14 days after surgery. Nivolumab was administered every two weeks after surgery. RESULTS: Toxicities of the combination were comparable to IL-12 gene monotherapy and were predictable, dose-related, and reversible upon withholding doses of VDX and/or nivolumab. VDX plasma pharmacokinetics demonstrate a dose-response relationship with effective brain tumor tissue VDX penetration and production of IL-12. IL-12 levels in serum peaked in all subjects at about Day 3 after surgery. Tumor IFNγ increased in post-treatment biopsies. Median overall survival (mOS) for VDX 10 mg with nivolumab was 16.9 months and for all subjects was 9.8 months. CONCLUSION: The safety of this combination immunotherapy was established and has led to an ongoing phase II clinical trial of immune checkpoint blockade with controlled IL-12 gene therapy (NCT04006119).

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Chiocca EA, Gelb AB, Chen CC, et al. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. Neuro Oncol. 2022. PMID: 34850166. doi:10.1093/neuonc/noab271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。